Open AccessSynthesis and Characterization of 3-(1-((3,4-Dihydroxyphenethyl)amino)ethylidene)-chroman-2,4-dione as a Potential Antitumor Agent
Author(s) -
Dušan Dimić,
Zoran Marković,
Luciano Saso,
Edina Avdović,
Jelena Đorović,
Isidora Petrović,
D. Stanisavljević,
Milena Stevanović,
Ivan Potočňák,
Erika Samoľová,
Srećko R. Trifunović,
Jasmina M. Dimitrić Marković
Publication year - 2019
Publication title -
oxidative medicine and cellular longevity
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.494
H-Index - 93
eISSN - 1942-0900
pISSN - 1942-0994
DOI - 10.1155/2019/2069250
Subject(s) - hacat , chemistry , in vitro , docking (animal) , cell culture , coumarin , stereochemistry , molecule , derivative (finance) , biochemistry , biology , organic chemistry , medicine , nursing , genetics , economics , financial economics
The newly synthesized coumarin derivative with dopamine, 3-(1-((3,4-dihydroxyphenethyl)amino)ethylidene)-chroman-2,4-dione, was completely structurally characterized by X-ray crystallography. It was shown that several types of hydrogen bonds are present, which additionally stabilize the structure. The compound was tested in vitro against different cell lines, healthy human keratinocyte HaCaT, cervical squamous cell carcinoma SiHa, breast carcinoma MCF7, and hepatocellular carcinoma HepG2. Compared to control, the new derivate showed a stronger effect on both healthy and carcinoma cell lines, with the most prominent effect on the breast carcinoma MCF7 cell line. The molecular docking study, obtained for ten different conformations of the new compound, showed its inhibitory nature against CDK S protein. Lower inhibition constant, relative to one of 4-OH-coumarine, proved stronger and more numerous interactions with CDK S protein. These interactions were carefully examined for both parent molecule and derivative and explained from a structural point of view.